NanoEcho strengthens management by hiring a clinical director

NanoEcho strengthens the organization by hiring Ulrika Axelsson as responsible for the company’s clinical operations. Ulrika will be part of the company’s executive management team and will, among other things, be responsible for planning and carrying out the company’s clinical studies, with the goal of getting market approval for NanoEcho’s system for rectal cancer diagnostics.

Ulrika has a PhD in immunotechnology and a broad experience from various leading positions with a clinical focus, within Life Science. She has led various multidisciplinary projects with stakeholders and partners from both companies, academia, and healthcare, which has included, among other things, planning and running clinical studies. Ulrika is currently active as a business coach within SmiLe Life Science Incubator and is expected to start her position as clinical director at NanoEcho in June.

“I am extremely happy that Ulrika has chosen to join us at NanoEcho. With her solid experience in life science and clinical studies, she will be a key person in our management team. I look forward to jointly intensifying preparations of our clinical registration study” says Linda Persson, CEO at NanoEcho.

“NanoEcho is a company with a very exciting product, and it will be really fun to join and take such an important role in the company,” says Ulrika Axelsson, incoming clinical director at NanoEcho.

If you have any questions, please contact:
Kristina Hallström, CMO & CCO
NanoEcho develops a new technology for clearer diagnostics of, in the first indication, rectal cancer. The imaging technology is based on a new medical approach where nanotechnology is used in combination with modern ultrasound technology. The images that are generated are intended to facilitate differentiation between healthy and diseased tissue and at the same time determine the location of the cancer tissue more precisely. The aim is to provide more precise, simple, and cost-effective diagnosis of cancers and other diseases. With clearer diagnostics, the company wants to assist treating physicians with better guidance for more personalised treatment. Both the quality of life of the patients and their chance of survival can improve after treatment, with reduced treatment costs.

Pågående emission
i NanoEcho

Erbjudande om att teckna aktier i NanoEcho AB (publ) i samband med IPO
Teckningstid: 29 maj – 28 juni

We use cookies to enhance your experience on our website and analyze our traffic. By clicking ‘Accept,’ you consent to our use of cookies. You can learn more about the types of cookies we use and how to manage them in our privacy policy.